Genetic Variability in Patients with HCV-Related Hepatocellular Carcinoma

References

• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424. doi:10.3322/caac.2149230207593
   PubMed Web of Science ®Google Scholar
• Sagnelli E, Macera M, Russo A, Coppola N, Sagnelli C. Epidemiological and etiological variations in hepatocellular carcinoma. Infection. 2020;48(1):7–17. PMID: 31347138. doi:10.1007/s15010-019-01345-y31347138
   PubMed Web of Science ®Google Scholar
• Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255. doi:10.1016/S0140-6736(11)61347-022353262
   PubMed Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, Razavi‐Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45‐57. doi:10.1016/j.jhep.2014.07.027
   Web of Science ®Google Scholar
• Dhanasekaran R, Bandoh S, Roberts LR. Molecular pathogenesis of hepatocellular carcinoma and impact of therapeutic advances. F1000Res. 2016;5:F1000 Faculty Rev–879. doi:10.12688/f1000research.6946.1
   Google Scholar
• Lin MV, King LY, Chung RT. Hepatitis C virus-associated cancer. Annu Rev Pathol. 2014;10:345–370. doi:10.1146/annurev-pathol-012414-04032325387053
   PubMed Web of Science ®Google Scholar
• Banerjee A, Ray RB, Ray R. Oncogenic potential of hepatitis C virus proteins. Viruses. 2010;2:2108–2133. doi:10.3390/v209210821994721
   PubMed Web of Science ®Google Scholar
• De Giorgi V, Monaco A, Worchech A, et al. Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med. 2009;7:85. doi:10.1186/1479-5876-7-8519821982
   PubMed Web of Science ®Google Scholar
• Bartsch H, Nair J. Oxidative stress and lipid peroxidation-derived DNA-lesions in inflammation driven carcinogenesis. Cancer Detect Prev. 2004;28:385–391. doi:10.1016/j.cdp.2004.07.00415582261
   PubMedGoogle Scholar
• Ogata F, Akuta N, Kobayashi M, et al. Amino acid substitutions in the hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by all-oral direct-acting antiviral regimens. J Med Virol. 2018;90(6):1087–1093. doi:10.1002/jmv.2504729427443
   PubMed Web of Science ®Google Scholar
• Nakamoto S, Imazeki F, Fukai K, et al. Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development. J Hepatol. 2010;52:72–78. doi:10.1016/j.jhep.2009.10.00119910070
   PubMed Web of Science ®Google Scholar
• Coppola N, Onorato L, Iodice V, et al. Occult HBV infection in HCC and cirrhotic tissue of HBsAg-negative patients: a virological and clinical study. Oncotarget. 2016;7(38):62706–62714. PMID: 27486882; PMCID: PMC5308760. doi:10.18632/oncotarget.1090927486882
   PubMedGoogle Scholar
• Coppola N, Potenza N, Pisaturo M, et al. Liver microRNA hsa-miR-125a-5p in HBV chronic infection: correlation with HBV replication and disease progression. PLoS One. 2013;8(7):e65336. PMID: 23843939; PMCID: PMC3701058. doi:10.1371/journal.pone.006533623843939
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. doi:10.1016/j.jhep.2011.12.00122424438
   PubMed Web of Science ®Google Scholar
• Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. PMID: 10518312. doi:10.1055/s-2007-100712210518312
   PubMed Web of Science ®Google Scholar
• Coppola N, Pisapia R, Tonziello G, et al. Improvement in the aetiological diagnosis of acute hepatitis C: a diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. J Clin Virol. 2009;46(3):222–229. PMID: 19758839. doi:10.1016/j.jcv.2009.08.00919758839
   PubMed Web of Science ®Google Scholar
• Pisaturo M, Starace M, Minichini C, et al. Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. Antivir Ther. 2019;24(7):485–493. PMID: 30758299. doi:10.3851/IMP329630758299
   PubMed Web of Science ®Google Scholar
• Selimovic D, El-Khattouti A, Ghozlan H, Haikel Y, Abdelkader O, Hassan M. Hepatitis C virus-related hepatocellular carcinoma: an insight into molecular mechanisms and therapeutic strategies. World J Hepatol. 2012;4:342–355. doi:10.4254/wjh.v4.i12.34223355912
   PubMedGoogle Scholar
• Kasprzak A, Adamek A. Role of hepatitis C virus proteins (C, NS3, NS5A) in hepatic oncogenesis. Hepat Res. 2008;38:1–26. doi:10.1111/j.1872-034X.2007.00261.x
   Web of Science ®Google Scholar
• Li HC, Ma HC, Yang CH, Lo SY. Production and pathogenicity of hepatitis C virus core gene products. World J Gastroenterol. 2014;20:7104–7122. doi:10.3748/wjg.v20.i23.710424966583
   PubMed Web of Science ®Google Scholar
• Tsuchihara K, Hijikata M, Fukuda K, Kuroki T, Yamamoto N, Shimotohno K. Hepatitis C virus core protein regulates cell growth and signal transduction pathway transmitting growth stimuli. Virology. 1999;258:100–107. doi:10.1006/.viro.1999.969410329572
   PubMed Web of Science ®Google Scholar
• Erhardt A, Hassan M, Heintges T, Haussinger D. Hepatitis C virus core protein induces cell proliferation and activates ERK, JNK, and p38 MAP kinases together with the MAP kinase phosphatase MKP-1 in a HepG2 Tet-Off cell line. Virology. 2002;292:272–284. doi:10.1006/viro.2001.122711878930
   PubMed Web of Science ®Google Scholar
• Hassan M, Ghozlan H, bdel-Kader O. Activation of RB/ E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells. Cell Signal. 2004;16:1375–1385. doi:10.1016/j.cellsig.2004.04.00515381253
   PubMed Web of Science ®Google Scholar
• Kwun HJ, Jung EY, Ahn JY, Lee MN, Jang KL. p53- dependent transcriptional repression of p21(waf1) by hepatitis C virus NS3. J Gen Virol. 2001;82:2235–2241. doi:10.1099/0022-1317-82-9-223511514734
   PubMed Web of Science ®Google Scholar
• Irshad M, Gupta P, Irshad K. Molecular basis of hepatocellular carcinoma induced by hepatitis C virus infection. World J Hepatol. 2017;9(36):1305–1314. PMID: 29359013; PMCID: PMC5756719. doi:10.4254/wjh.v9.i36.130529359013
   PubMed Web of Science ®Google Scholar
• Ghosh AK, Steele R, Meyer K, Ray R, Ray RB. Hepatitis C virus NS5A protein modulates cell cycle regulatory genes and promotes cell growth. J Gen Virol. 1999;80:1179–1183. doi:10.1099/0022-1317-80-5-117910355764
   PubMed Web of Science ®Google Scholar
• Majumder M, Ghosh AK, Steele R, Ray R, Ray RB. Hepatitis C virus NS5A physically associates with p53 and regulates p21/waf1 gene expression in a p53-dependent manner. J Virol. 2001;75:1401–1407. doi:10.1128/JVI.75.3.1401-1407.200111152513
   PubMed Web of Science ®Google Scholar
• Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kB. Proc Natl Acad Sci U S A. 2001;98:9599–9604. doi:10.1073/pnas.17131129811481452
   PubMed Web of Science ®Google Scholar
• Wu SC, Chang SC, Wu HY, Liao PJ, Chang MF. Hepatitis C virus NS5A protein down-regulates the expression of spindle gene Aspm through PKR-p38 signaling pathway. J Biol Chem. 2008;283(43):29396–29404. PMID: 18728014; PMCID: PMC2662026. doi:10.1074/jbc.M80282120018728014
   PubMed Web of Science ®Google Scholar
• Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009;100(12):2465–2468. doi:10.1111/j.1349-7006.2009.01338.x20175782
   PubMed Web of Science ®Google Scholar
• Pérez PS, Di Lello FA, Mullen EG, et al. Compartmentalization of hepatitis C virus variants in patients with hepatocellular carcinoma. Mol Carcinog. 2017;56(2):371–380. PMID: 27163636. doi:10.1002/mc.2250027163636
   PubMed Web of Science ®Google Scholar
• Harouaka D, Engle RE, Wollenberg K, et al. Diminished viral replication and compartmentalization of hepatitis C virus in hepatocellular carcinoma tissue. Proc Natl Acad Sci U S A. 2016;113(5):1375–1380. PMID: 26787866; PMCID: PMC4747736. doi:10.1073/pnas.151687911326787866
   PubMed Web of Science ®Google Scholar
• El-Shamy A, Pendleton M, Eng FJ, Doyle EH, Bashir A, Branch AD. Impact of HCV core gene quasispecies on hepatocellular carcinoma risk among HALT-C trial patients. Sci Rep. 2016;1(6):27025. doi:10.1038/srep27025
   Web of Science ®Google Scholar
• Moreira JP, Malta FM, Diniz MA, et al. Interferon lambda and hepatitis C virus core protein polymorphisms associated with liver cancer. Virology. 2016;493:136–141. doi:10.1016/j.virol.2016.03.00827035616
   PubMed Web of Science ®Google Scholar
• Sorbo MC, Carioti L, Bellocchi MC, et al. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma. Liver Int. 2019;39(10):1986–1998. PMID: 31172639. doi:10.1111/liv.1416831172639
   PubMed Web of Science ®Google Scholar